Digitalis Revisited: Old Heart Drug Cuts HF Hospitalizations by 25%
A JAMA meta-analysis of 9,000+ patients finds digitalis glycosides significantly reduce worsening heart failure events, reigniting interest in a centuries-old drug.
Summary
A major meta-analysis published in JAMA pooled data from three large placebo-controlled trials involving over 9,000 heart failure patients. Researchers found that digitalis glycosides — a drug class used for centuries — reduced the combined risk of cardiovascular death or worsening heart failure by 15%. This benefit was driven primarily by a 25% reduction in hospitalizations or acute deterioration events. Importantly, the drugs did not significantly reduce cardiovascular death or all-cause mortality on their own. The findings held regardless of which specific digitalis drug was used or how intensive the patient's background heart failure therapy was. These results suggest digitalis glycosides could be reconsidered as an add-on treatment option for patients with reduced or mildly reduced heart function who remain symptomatic despite standard care.
Detailed Summary
Heart failure remains one of the leading causes of hospitalization and death globally, and despite remarkable advances in therapy, many patients continue to deteriorate. Digitalis glycosides — derived from the foxglove plant and used in medicine for over 200 years — fell out of favor as newer drug classes emerged, but their precise role in modern heart failure management has remained unclear.
This meta-analysis, published in JAMA, systematically reviewed placebo-controlled randomized trials of digitalis glycosides in patients with heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF). Three trials met the strict inclusion criteria, together enrolling 9,013 patients with a mean age of 64.5 years, 22% of whom were women.
The primary composite endpoint — cardiovascular death or first worsening heart failure event — occurred in 41% of patients on digitalis versus 45% on placebo, yielding a hazard ratio of 0.85 (95% CI, 0.80–0.90; P<0.001). The most striking individual finding was a 25% relative reduction in worsening heart failure events (HR 0.75). However, neither cardiovascular death (HR 0.99) nor all-cause mortality (HR 0.97) were significantly reduced, suggesting the drugs prevent acute decompensation rather than alter long-term survival trajectories.
Notably, there was no significant interaction by trial, type of glycoside, or intensity of background therapy — meaning the benefit appeared consistent regardless of whether patients were on modern guideline-directed medical therapy.
For clinicians managing patients who remain symptomatic despite optimized standard care, these data offer a statistical basis for revisiting digitalis as adjunctive therapy. The results are particularly relevant for patients with HFmrEF, a group with fewer established treatment options. Caution is warranted given digitalis's narrow therapeutic window and historical toxicity concerns.
Key Findings
- Digitalis glycosides reduced the composite of CV death or worsening HF by 15% (HR 0.85) across 9,013 patients.
- Worsening heart failure events were reduced by 25% (HR 0.75), the primary driver of the composite benefit.
- No significant reduction in cardiovascular death (HR 0.99) or all-cause mortality (HR 0.97) was observed.
- Benefit was consistent regardless of background heart failure therapy intensity or type of digitalis used.
- Findings support considering digitalis as add-on therapy in HFrEF and HFmrEF patients who remain symptomatic.
Methodology
This is a fixed-effects meta-analysis of three placebo-controlled randomized clinical trials with more than 1,000 patients each, identified via PubMed search through March 2026. Risk of bias was assessed using the Cochrane Risk of Bias tool version 2, and PRISMA reporting guidelines were followed. The primary endpoint was a composite of time to cardiovascular death or first worsening heart failure event.
Study Limitations
The summary is based on the abstract only, as the full text was not available; key details on patient subgroups, dosing, and adverse event rates could not be reviewed. Only three trials met inclusion criteria, all with older trial designs that may not reflect current standard-of-care background therapy. The study cannot fully account for digitalis toxicity risks in real-world settings, where patient monitoring may be less rigorous than in trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.